Protection from experimental autoimmune diabetes in the non‐obese diabetic mouse with soluble interleukin‐1 receptor
Ferdinando Nicoletti(University of Catania), Pier Luigi Meroni(IRCCS Istituto Auxologico Italiano), Roberto Di Marco(University of Catania), Hans U. Schorlemmeru(Behringwerke (Germany)), Roland Kurrleu(Behringwerke (Germany)), Michele Lunettau(University of Milan), Paola Zacconeu(University of Milan), Gaetano Magro(University of Catania), Sebastiano Grasso(University of Catania), Wilma Barcellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)
Cited by 87
Related Papers
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
|Journal of Thrombosis and Haemostasis|2006|7.1k
Natural products in drug discovery: advances and opportunities
|Nature Reviews Drug Discovery|2021|5.2k
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
|Oncotarget|2011|579
GSK-3 as potential target for therapeutic intervention in cancer
|Oncotarget|2014|508